Evidence for a genetic role in varicose veins and chronic venous insufficiency

Phlebology

Volumn 27, Issue 7, 2012, Pages 329-335

  Krysa, J ^a   Jones, G T ^a   van Rij, A M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Genetics; Genome wide scan; Varicose veins; Venous

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 13; ESTROGEN; ESTROGEN RECEPTOR BETA; RNA; THROMBOMODULIN; TRANSCRIPTION FACTOR FOXC2; TUMOR NECROSIS FACTOR ALPHA;

AUTOSOMAL DOMINANT INHERITANCE; CHRONIC VEIN INSUFFICIENCY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DIZYGOTIC TWINS; DNA POLYMORPHISM; FAMILY; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MUTATION; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMOCHROMATOSIS; HEREDITY; HERITABILITY; HUMAN; LYMPHEDEMA DISTICHIASIS; MONOZYGOTIC TWINS; PATHOGENESIS; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOPHILIA; VALIDATION PROCESS; VALIDITY; VARICOSIS;

CHRONIC DISEASE; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THROMBOMODULIN; VARICOSE VEINS; VENOUS INSUFFICIENCY;

EID: 84872872357     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1258/phleb.2011.011030     Document Type: Review

References (56)

1. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Community Health 1999;53:149-53
2. Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg 2009;96:1231-42
3. Virchow. In: Warwick W. The rational treatment of varicose veins and varicocoele. 1855
4. Warwick WT. The rational treatment of varicose veins and varicocoele 1931. London: Faber and Faber
5. Brinsuk M, Tank J, Luft FC, Busjahn A, Jordan J. Heritability of venous function in humans. Arterioscler Thromb Vasc Biol 2004;24:207-11
6. McPheeters HO, Anderson JK. Treatment of Varicose Veins and Hemorrhoids. 3rd edn. Philadelphia, PA: Davis, 1938
7. Pratt GH. Differential diagnosis and treatment of pathologically enlarged veins. Med Clin North Am 1950;34: 897-908
8. Cornu-Thenard A, Boivin P, Baud JM, De Vincenzi I, Carpentier PH. Importance of the familial factor in varicose disease. Clinical study of 134 families. J Dermatol Surg Oncol 1994;20:318-26
9. Guo Q, Guo C. Genetic analysis of varicose vein of lower extremities. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 1998;15:221-3
10. Ahti TM, Makivaara LA, Luukkaala T, Hakama M, Laurikka JO. Effect of family history on the incidence of varicose veins: a population-based follow-up study in Finland. Angiology 2009;60:487-91
11. Fiebig A, Krusche P, Wolf A, et al. Heritability of chronic venous disease. Hum Genet 2010;127:669-74
12. Cario-Toumaniantz C, Boularan C, Schurgers LJ, et al. Identification of differentially expressed genes in human varicose veins: involvement of matrix gla protein in extracellular matrix remodeling. J Vasc Res 2007;44:444-59
13. Kim DI, Eo HS, Joh JH. Identification of differentially expressed genes in primary varicose veins. J Surg Res 2005;123:222-6
14. Hollingsworth SJ, Powell G, Barker SG, Cooper DG. Primary varicose veins: altered transcription of VEGF and its receptors (KDR, flt-1, soluble flt-1) with saphenofemoral junction incompetence. Eur J Vasc Endovasc Surg 2004;27:259-68
15. Lee S, Lee W, Choe Y, et al. Gene expression profiles in varicose veins using complementary DNA microarray. Dermatol Surg 2005;31:391-5
16. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33(Suppl 1):245-54
17. Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res 2008;102: 873-87
18. Kuczenski RS, Aggarwal K, Lee KH. Improved understanding of gene expression regulation using systems biology. Expert Rev Proteomics 2005;2:915-24
19. Liu Y, Ringner M. Revealing signaling pathway deregulation by using gene expression signatures and regulatory motif analysis. Genome Biol 2007;8:R77
20. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulindependent diabetes mellitus. Diabetes 1984;33:176-83
21. Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 2002;39:478-83
22. Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007;115:1912-20
23. Le Flem L, Mennen L, Aubry ML, et al. Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler Thromb Vasc Biol 2001;21:445-51
24. Le Flem L, Picard V, Emmerich J, et al. Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler Thromb Vasc Biol 1999;19:1098-104
25. Sverdlova AM, Bubnova NA, Baranovskaya SS, Vasina VI, Avitisjan AO, Schwartz EI. Prevalence of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with varicose veins of lower limbs. Mol Genet Metab 1998;63:35-6
26. Zamboni P, Tognazzo S, Izzo M, et al. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg 2005;42:309-14
27. Singh AV, Subhashree L, Milani P, Gemmati D, Zamboni P. Interplay of iron metallobiology, metalloproteinases, and FXIII, and role of their gene variants in venous leg ulcer. Int J Low Extrem Wounds 2010;9:166-79
28. Gemmati D, Federici F, Catozzi L, et al. DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators. J Vasc Surg 2009;50:1444-51
29. Hildenbrand T, Idzko M, Panther E, Norgauer J, Herouy Y. Treatment of non-healing leg ulcers with fibrin-stabilizing factor XIII: a case report. Dermatol Surg 2002;28: 1098-9
30. Wozniak G, Dapper F, Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Semin Thromb Hemost 1996;22:445-50
31. Gemmati D, Tognazzo S, Serino ML, et al. Factor XIII V34L polymorphism modulates the risk of chronic venous leg ulcer progression and extension. Wound Repair Regen 2004;12:512-7
32. Gemmati D, Tognazzo S, Catozzi L, et al. Influence of gene polymorphisms in ulcer healing process after superficial venous surgery. J Vasc Surg 2006;44:554-62
33. Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997;3:1209-15
34. Ashcroft GS, Greenwell-Wild T, Horan MA, Wahl SM, Ferguson MW. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol 1999;155:1137-46
35. Ashworth JJ, Smyth JV, Pendleton N, et al. Polymorphisms spanning the 0N exon and promoter of the estrogen receptor-beta (ERbeta) gene ESR2 are associated with venous ulceration. Clin Genet 2008;73:55-61
36. Hajeer AH, Hutchinson IV. Influence of TNF alpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001;62:1191-9
37. Wallace HJ, Stacey MC. Levels of tumor necrosis factoralpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. J Invest Dermatol 1998;110:292-6
38. Wallace HJ, Vandongen YK, Stacey MC. Tumor necrosis factor-alpha gene polymorphism associated with increased susceptibility to venous leg ulceration. J Invest Dermatol 2006;126:921-5
39. Bradbury AW, MacKenzie RK, Burns P, Fegan C. Thrombophilia and chronic venous ulceration. Eur J Vasc Endovasc Surg 2002;24:97-104
40. Mackenzie RK, Ludlam CA, Ruckley CV, Allan PL, Burns P, Bradbury AW. The prevalence of thrombophilia in patients with chronic venous leg ulceration. J Vasc Surg 2002;35:718-22
41. Sam RC, Burns PJ, Hobbs SD, et al. The prevalence of hyperhomocysteinemia, methylene tetrahydrofolate reductase C677T mutation, and vitamin B12 and folate deficiency in patients with chronic venous insufficiency. J Vasc Surg 2003;38:904-8
42. Darvall KA, Sam RC, Adam DJ, Silverman SH, Fegan C., Bradbury AW. Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls. J Vasc Surg 2009;49:1235-41
43. Pistorius MA. Chronic venous insufficiency: the genetic influence. Angiology 2003;54(Suppl. 1): S5-12
44. Freely associating. Nat Genet 1999;22:1-2
45. Donahue MP, Kraus WE. Genetic association studies; the good, the bad, and the ugly. Am Heart J 2007;154:610-2
46. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53
47. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491-3
48. Visel A, Zhu Y, May D, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010;464:409-13
49. Holdt LM, Beutner F, Scholz M, et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol;30:620-7
50. Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med 2009;360:1759-68
51. Zhong H, Yang X, Kaplan LM, Molony C, Schadt EE. Integrating pathway analysis and genetics of gene expression for genome-wide association studies. Am J Hum Genet 2010;86:581-91
52. Lotta LA. Genome-wide association studies in atherothrombosis. Eur J Intern Med 2010;21:74-8
53. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics 43:333-8
54. Zondervan KT, Cardon LR. Designing candidate gene and genome-wide case-control association studies. Nat Protoc 2007;2:2492-501
55. Staffa R. Chronic venous insufficiency-epidemiology. Bratisl Lek Listy 2002;103:166-8
56. Herrington D. Eliminating the improbable: Sherlock Holmes and standards of evidence in the genomic age. Circulation 2005;112:2081-4